anti-c-Met IgG-oxaliplatin

Anti-c-Met IgG-oxaliplatin is an experimental antibody-drug conjugate (ADC) developed for targeted chemotherapy of c-Met-positive hepatocellular carcinoma (HCC). This drug uses a humanized monoclonal antibody targeting the c-Met receptor tyrosine kinase, conjugated via a dipeptide-p-amidobenzyl alcohol linker to the cytotoxic chemotherapy agent oxaliplatin. Each antibody is loaded with approximately 4.35 moles of oxaliplatin. The ADC demonstrates selective binding to c-Met-positive HepG2 cells, with high cytotoxicity specific to these cells and significantly reduced off-target effects compared to free oxaliplatin. In preclinical models, the conjugate was shown to reduce common oxaliplatin toxicity, such as diarrhoea, weight loss, and organ atrophy, while maintaining antitumor activity. The technology aims to improve the therapeutic index by exploiting the targeting properties of monoclonal antibodies to deliver cytotoxic payloads directly to tumor cells, thereby limiting damage to normal tissues[1][2][3].

Other names

anti-c-Met IgG conjugated to oxaliplatinHigh-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatinanti-c-Met IgG-OXA